Abstract

The human microbiome, particularly the gut microbiota, plays a central role in shaping immune development, 
homeostasis, and function. Increasing evidence suggests that inter-individual variation in microbial composition 
and diversity may influence vaccine responses, potentially accounting for disparities in immunogenicity across 
populations and age groups. Animal models have demonstrated that microbial molecules act as natural adjuvants, 
modulating innate and adaptive immune pathways critical for effective immunization. Human clinical and 
observational studies, though heterogeneous and often inconclusive, indicate associations between microbiome 
composition, vaccine-induced antibody responses, and adverse effects. Specific vaccines including influenza, 
COVID-19, and pediatric immunizations have shown variable outcomes linked to gut microbial diversity, 
metabolites such as short-chain fatty acids, and immunomodulatory taxa. Interventions with probiotics, prebiotics, 
and dietary strategies have yielded mixed results but remain promising approaches for enhancing vaccine efficacy. 
Methodological challenges, population variability, and ethical considerations complicate the translation of 
microbiome research into actionable vaccination strategies. Future directions emphasize longitudinal, multi-omics 
studies, systems vaccinology, and personalized approaches integrating microbiome profiling into vaccine 
development and policy. A deeper understanding of microbiota–immune interactions holds the potential to 
optimize immunization outcomes and strengthen public health programs globally.